Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI or VR: which High-Tech classroom helps kids with ADHD best?

NCT ID NCT07392463

Symptom relief Sponsor: Tongren Hongxin Kangxin Traditional Chinese Medicine Hospital, Guizhou Province Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two high-tech teaching methods—AI-assisted learning and virtual reality classrooms—in 90 children aged 8-15 with ADHD. Over 12 weeks, researchers measured changes in ADHD symptoms and thinking skills. The goal was to see if these digital tools can help without medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence-assisted teaching and virtual reality-based smart classroom teaching
What this could lead to
If successful, this could point toward effective non-drug educational tools to help children with ADHD manage symptoms and improve focus.
What could go wrong
This is a small, completed trial with 90 participants, so results may not apply to all children with ADHD. The interventions are behavioral, not medical, so benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children and adolescents aged 8 to 15 years. * Diagnosis of attention-deficit/hyperactivity disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by two qualified child psychiatrists. * Total score of 25 or higher on the ADHD Rating Scale (ADHD-RS). * Intelligence quotient (IQ) of 80 or above as assessed by the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV). * Stable clinical status for at least 30 days prior to enrollment, with adherence to standard first-line or second-line treatment regimens, and no planned changes in treatment during the study period. * Ability to participate in structured digital teaching sessions. * Written informed consent provided by a parent or legal guardian, with assent obtained from the participant when appropriate. Exclusion Criteria: * Presence of neurodevelopmental or neurological disorders other than ADHD, such as cerebral palsy or epilepsy. * Diagnosis of severe psychiatric disorders, including schizophrenia. * Significant sensory impairments (e.g., hearing impairment) that could interfere with study participation. * Lack of response to two or more different classes of ADHD medications. * History of suspected substance abuse or dependence within the past 6 months. * Physical conditions or motor impairments that would prevent participation in the teaching interventions. * Current suicidal ideation or severe suicidal behavior as determined by the investigator. * Receipt of other structured psychological or educational interventions during the study period. * Any other condition that, in the opinion of the investigator, would make participation in the study inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention deficit hyperactivity disorder

Contacts and locations

Locations

  • Hongxinkang New Traditional Chinese Medicine Hospital, Tongren

    Tongren, Guizhou, 554300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.